FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and pharmacy. Disclosed is a pharmaceutical composition for oral administration for treating or preventing a disorder of the upper gastrointestinal tract, selected from dyspepsia, epigastric burning, erosive oesophagitis, gastroesophageal reflux disease, peptic ulcer, oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma containing a therapeutically effective amount of at least one bile acid sequestrant selected from one or more substances from colesevelam, colesevelam hydrochloride, sevelamer and combinations thereof, and a gastric retention carrier composition containing one or more hydrogels, wherein the composition expands upon contact with gastric juice. Also disclosed is a sustained release pharmaceutical dosage form containing the above composition and a method for prevention or treatment of an upper gastrointestinal disorder comprising administering a therapeutically effective amount of the declared composition or pharmaceutical dosage form.
EFFECT: technical result consists in the implementation of the declared application, wherein releasing the colesevelam from the composition takes place in the stomach for more than 9 hours.
13 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS AND COMPOSITIONS FOR TREATING OESOPHAGEAL DISORDERS | 2007 |
|
RU2491075C2 |
NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2241462C2 |
SOLID MEDICINAL FORM, CONTAINING PROTON PUMP INHIBITOR, AND SUSPENSION OBTAINED FROM IT | 2005 |
|
RU2397756C2 |
PHARMACEUTICAL COMBINATION COMPRISING IBAT-INHIBITOR AND BILE ACID BINDER | 2011 |
|
RU2619215C2 |
IBAT INHIBITOR FOR TREATING HEPATIC DISORDERS | 2011 |
|
RU2591188C2 |
COMBINATION OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS | 2017 |
|
RU2742033C2 |
PHARMACEUTICAL COMPOSITION CONTAINING A PROTON PUMP INHIBITOR AND ANTACID | 2020 |
|
RU2807610C1 |
MONOHYDRATE OF SODIUM SALT OF S-TENATOPRAZOL AND ITS USE AS INHIBITOR OF PROTON PUMP | 2005 |
|
RU2376304C2 |
ORAL THERAPY OF VITAMIN B DEFICIENCY | 2011 |
|
RU2576511C2 |
DRUG FROM GASTROESOPHAGEAL REFLUX DISEASE | 2013 |
|
RU2635766C2 |
Authors
Dates
2019-11-07—Published
2013-04-17—Filed